Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling Review

   


Authors: Holstein, S. A.; Howard, A.; Avigan, D.; Bhutani, M.; Cohen, A. D.; Costa, L. J.; Dhodapkar, M. V.; Gay, F.; Gormley, N.; Green, D. J.; Hillengass, J.; Korde, N.; Li, Z.; Mailankody, S.; Neri, P.; Parekh, S.; Pasquini, M. C.; Puig, N.; Roodman, G. D.; Samur, M. K.; Shah, N.; Shah, U. A.; Shi, Q.; Spencer, A.; Suman, V. J.; Usmani, S. Z.; McCarthy, P. L.
Review Title: Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Abstract: The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled “Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.” This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions. © 2020 American Society for Transplantation and Cellular Therapy
Keywords: antibiotic agent; overall survival; lenalidomide; review; cancer combination chemotherapy; drug safety; nonhuman; cancer patient; flow cytometry; dendritic cell vaccine; cancer immunotherapy; multiple myeloma; health survey; dexamethasone; immunoglobulin; autologous stem cell transplantation; diagnostic imaging; cancer research; soft tissue; plasma cell; minimal residual disease; laboratory test; chimeric antigen receptor; cell therapy; tumor immunity; bone marrow transplantation; health care organization; adoptive immunotherapy; hematologic disease; clinical trial (topic); workshop; endpoint; immune dysregulation; high throughput sequencing; immunological procedures; immunobiology; nivolumab; smoldering multiple myeloma; human; car t cell; daratumumab; positron emission tomography-computed tomography; chimeric antigen receptor t-cell immunotherapy; immune profiling
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 26
Issue: 10
ISSN: 1083-8791
Publisher: Elsevier Inc.  
Date Published: 2020-10-01
Start Page: e247
End Page: e255
Language: English
DOI: 10.1016/j.bbmt.2020.06.011
PUBMED: 32589921
PROVIDER: scopus
PMCID: PMC7529908
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087955631&doi=10.1016%2fj.bbmt.2020.06.011&partnerID=40&md5=012e7e207eab423db657986de4d92980
Notes: Review -- Export Date: 2 November 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Neha Sanat Korde
    226 Korde
  2. Sham Mailankody
    282 Mailankody
  3. Urvi A Shah
    187 Shah
Related MSK Work